DailyIQ
Last updatedjust now

ALNY·Alnylam Pharmaceuticals, Inc.

$239.46
-5.99 (-2.44%)
Market Closed (Overnight)$239.60+0.14 (+0.06%)
High
$247.10
Open
$245.82
Market Cap
32.12B
52W High
$495.55
Low
$238.51
P. Close
$239.46
P/E
39.75
52W Low
$197.81
Fwd P/E
19.34
DailyIQ Est.
$397.03
Inst. Ownership
-
Short Interest
4.73%
Days to Cover
3.9
Technical Score (1D)
41
SELL
News Sentiment
53
MIXED
Alnylam’s latest investor call, just 19.4 hours ago, highlighted the RNAi candidate zilebesiran as a potential mid‑term asset for continuous blood‑pressure control in high‑risk patients, but the company offered no new clinical data or milestone dates. The discussion reiterated confidence in the RNAi platform’s transformative potential, yet the absence of concrete timelines keeps the upside speculative for the next trading week. A few hours earlier, Alnylam released a slide deck that detailed preclinical results, dosing strategies, and a roadmap to first‑in‑human studies for zilebesiran, again without altering the current clinical or commercial milestones. Together, these two releases suggest that the company is still in the early development phase, with no immediate change in the expected launch window. For traders, the key implication is that the stock’s short‑term movement will likely hinge on forthcoming data releases or regulatory feedback rather than on the current presentations. Watch for the next clinical update, which could confirm a first‑in‑human start date or provide efficacy signals that would materially shift the pipeline’s trajectory. Also keep an eye on any FDA comments that might accelerate or delay the program, as these could create a catalyst within the next 1–10 trading days. Finally, monitor Alnylam’s broader RNAi portfolio for any cross‑program synergies that might influence investor sentiment once the zilebesiran data become available.
Earnings Summary
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, offering approved products such as ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, and Leqvio that treat hereditary amyloidosis, acute hepatic porphyria, and hypercholesterolemia, and it operates within the competitive biotechnology sector. In the most recent quarters, Alnylam reported a Q4 2025 EPS of $1.25 versus an estimate of $2.21, a miss, while revenue of $1.097B fell short of the $1.139B estimate, marking a slight decline from the prior Q4 2024 EPS of $0.06 and revenue of $593M. The company’s Q1 2026 EPS of $1.99 beat the $0.95 estimate, and revenue of $1.167B surpassed the $1.136B estimate, indicating a rebound in profitability and sales. Q2 2026 EPS of $1.84 beat the $1.59 estimate, but revenue of $1.291B missed the $1.350B estimate, suggesting a modest revenue slowdown while earnings remained resilient. Historically, Alnylam has shown a YoY revenue growth trajectory of roughly 20% from 2024 to 2025, with consistent EPS beats in the last three quarters despite occasional revenue misses, reflecting strong pricing power and cost management. Recent news highlights include updated clinical data for lead RNAi candidates presented at the Wells Fargo Healthcare Conference, reinforcing pipeline momentum and signaling potential regulatory milestones; the company’s partnership strategy and upcoming filing dates are key watch points, as are the regulatory status of its hypertension candidate zilebesiran and the planned U.S. launch of Nucresiran, which could materially impact near‑term revenue. Investors should watch for forthcoming FDA or EMA feedback on liver and ocular programs, the timing of Nucresiran’s launch, and any new efficacy data that could confirm the platform’s viability, as these factors will likely drive the next quarter’s earnings trajectory.

EPS

EstBeatMiss
$-0.51$0.29$1.09$1.89$2.68Q4'24Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.32 - -
Q2'26$1.59$1.84+16.0%
Q1'26$0.95$1.99+108.9%
Q4'25$2.21$1.25-43.4%
Q4'24$-0.14$0.06+142.5%

Revenue

EstBeatMiss
$462M$746M$1.0B$1.3B$1.6BQ4'24Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.5B - -
Q2'26$1.3B$1.3B-4.4%
Q1'26$1.1B$1.2B+2.7%
Q4'25$1.1B$1.1B-3.7%
Q4'24 - $593M -

Market Data

ALNY Stock Snapshot

HOLD41/100
$239.60+$0.14 (0.1%)
Market cap
32.12B
P/E ratio
39.8
Day range
$238.51 – $247.10
News sentiment
53/100 · Neutral
Analyst target
$371.35 (+55.0%)
Consensus
Buy · 40 analysts
52-week range+21.1% off low · -51.6% from high
$197.81$495.55
Price $239.60 DailyIQ Est. $397.03

Neither side has the upper hand on ALNY right now, and the indicator set reflects that. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What ALNY's own history says about today's numbers

Realized volatility (21d)
42.2% 46th pct
Below its peak
-51.2%
vs 200-day average
-23.5%
Up days (1y)
48%

Alnylam Pharmaceuticals, Inc. is currently running 42.2% annualised volatility over the last 21 sessions. Measured against ALNY's own 13 years of daily returns rather than a market-wide average, that is the 46th percentile close to its own typical level, against a typical reading of 43.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ALNY is trading -51.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -30.6%, and the deepest was -66.9% in 2016. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -23.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 10th percentile a narrower gap than it typically runs. Over the past year ALNY closed higher on 48% of sessions, and it is currently 1 session into a falling streak.

On September specifically: over 13 years of records, ALNY finished the month higher 5 of 13 times, with a median return of -1.8% and an average of -0.3%. Its strongest month historically has been August at +9.6% on average, its weakest October at -5.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ALNY has opened more than 2% away from the prior close in 240 of 3,266 sessions (7.3% of the time), with the largest gaps running +40.9% and -18.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ALNY moved an average of 3.3% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.8% and a largest of -5.6%.

All figures computed from 3,267 daily closes between 2013-09-19 and 2026-09-18, split-adjusted, recomputed daily. Percentiles are against ALNY's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ALNY's sector?

Alnylam Pharmaceuticals, Inc. sits in the Health Care sector, currently ranked 4th of 11 GICS sectors by relative-strength rotation score (improving).

Sector rank
#4 of 11
Sector state
Improving
Sector rotation score
100

Options Market

What is the options market pricing for ALNY?

CallsPuts

For Alnylam Pharmaceuticals, Inc.'s nearest expiry (2026-10-16, 27 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.69), with at-the-money implied volatility around 49.5%. The options market is pricing roughly a ±13.3% move by that expiry — a range of about $204.31–$267.01.

Put/call ratio (2026-10-16)
0.69
ATM implied volatility
49.5%
Total open interest
3,748
Expected move by 2026-10-16
±13.3% ($204.31–$267.01)

Analyst Rating Changes

Are analysts turning bullish or bearish on ALNY?

Jefferies most recently reiterated its rating on Alnylam Pharmaceuticals, Inc. to Hold on Sep 8, 2026 with a price target of $260 (from $230). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
JefferiesHold
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Sep 8, 2026JefferiesMaintainedHold$230 → $260
Sep 2, 2026HC Wainwright & Co.ReiteratedBuy$455
Aug 19, 2026BMO CapitalInitiatedOutperform$318
Aug 14, 2026Wells FargoMaintainedEqual-Weight$316 → $256
Aug 4, 2026Truist SecuritiesMaintainedBuy$410 → $315
Aug 4, 2026HC Wainwright & Co.MaintainedBuy$485 → $455
Aug 3, 2026Raymond JamesUpgradeOutperform → Strong Buy$420
Aug 3, 2026CitigroupMaintainedBuy$380 → $340
Aug 3, 2026BarclaysMaintainedOverweight$527 → $450
Jul 31, 2026JP MorganMaintainedOverweight$400 → $375
Jul 31, 2026RBC CapitalMaintainedOutperform$445 → $350
Jul 31, 2026Morgan StanleyMaintainedEqual-Weight$400 → $300

ALNY Competitive Positioning

Alnylam Pharmaceuticals, Inc. (ALNY) is tracked alongside these names in Biotechnology on DailyIQ — ranked by market cap, with today's move alongside.